Alector, Inc. is a clinical stage biopharmaceutical company dedicated to developing therapies for treating neurodegeneration diseases. The company has several products in different stages of clinical trials to target Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases. Alector, Inc. also collaborates with Adimab, LLC and GlaxoSmithKline plc to research and develop antibodies to treat neurodegenerative diseases.